Acronym

READI

Title

Research in Europe and Diversity Inclusion

Duration

Jan 2025 – Dec 2030

GA Number

101166227

Programme

Horizon Europe

Action type

RIA

Call

HORIZON-JU-IHI-2023-04-two-stage

Field

• Health
• Multistakeholder Engagement
• Social Innovation

Coordinator

SERMAS – Servicio Madrileno de Salud

Description

READI aims to enhance the representativeness of underserved (US) and underrepresented (UR) populations in clinical studies by fostering a more cohesive and integrated clinical study ecosystem. SHINE leads one task in the project: T6.2 Build READI community clusters. Besides WP6, SHINE has considerable efforts in the definition of the US/UR groups (WP1) and preparation of the training materials (WP4).

Website

ihi-readi.org

Social Media

• https://www.linkedin.com/company/readi-project
• https://www.youtube.com/@IHIREADIProject

Partners

• AbbVie – Aarhus Universitet (AU)
• Aarhus Universitetshospital (AUH)
•  Almirall SA (ALM)
• AstraZeneca AB (AZ)
• Boehringer Ingelheim – Breakthrough T1D (BREAKTHROUGH1D)
• Bristol-Myers Squibb Company Corp (BMS)
• CDISC Europe Foundation (CDISC)
• Chiesi Group
• Curewiki
• Digestive Cancers Europe (DiCE)
• Eli Lilly and Company (Lilly)
• Esperity (CT.be)
• European AIDS Treatment Group (EATG)
• European University Cyprus (EUC)
• ECRIN European Clinical Research Infrastructure Network (ECRIN)
• Hoffmann-La Roche AG (Roche)
• FIBHUG (Fundación para la Investigación Biomédica del Hospital Universitario de Getafe – Fundación para la Investigación Biomédica del Hospital Universitario la Paz (FIBHULP)
• FISABIO (Fundacion para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana)
• Forum des Patients Européens (EPF)
• Fundación 29 de Febrero – Fundació Privada per a la Recerca i la Docència Sant Joan de Déu (FSJD)
• GlaxoSmithKline Research & Development Limited (GSK)
• Global Heart Hub (GHH)
• HL7 International Fondation
• Information Technology for Translational Medicine (ITTM)
• SA – Irish Platform for Patients’ Organisations Science and Industry (IPPOSI)
• Janssen-Cilag Limited, a Johnson & Johnson company – Klinikum der Universität zu Köln (UHC)
• Medicines and Healthcare Products Regulatory Agency (MHRA)
• Midtjyllands EU Kontor Forening (CDEU)
• National Cancer Institute (NCI)
• National Institute for Health and Care Excellence (NICE)
• Novo Nordisk A/S – Pagalbos Onkologiniams Ligoniiams Asociacija (POLA)
• Penta Foundation (PENTA)
• Pfizer Inc (Pfizer)
• Sanofi
• SHINE 2Europe LDA (SHINE)
• Socialit Software e Consulting Srl (SIT)
• Stichting EUPATI Foundation (EUPATI)
• Stichting VU
• Synapse Research Management Partners SL (Synapse)
• Synergist Services (Synerserv)
• Takeda Pharmaceuticals International AG (TPIZ)
• The August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
• Trial Nation (TrialNation)
• UCB Biopharma (UCB)
• Universitair Medisch Centrum Utrecht (UMCU)
• University of Nicosia (UNIC)
• University Court of the University of Aberdeen (UoA)
• Vicomtech
• ViiV Healthcare UK LTD
• VU University Medical Center (VU)
• Youth Cancer Europe (YCE)
• Zabala Innovation Consulting SA (ZABALA)